Advaxis Canine Cancer Vaccine Featured on ABC News

Advaxis

announced that ADXS-cHER2, its proprietary immunotherapy for the treatment of breast cancer and canine osteosarcoma, was featured on ABC News in an article titled “Bone Cancer Vaccine for Dogs Shows Promise for Breast Cancer”. Advaxis sponsored a Phase 1 canine osteosarcoma study, conducted by Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine, evaluating the safety and efficacy of Advaxis' proprietary immunotherapy, ADXS-cHER2, in companion dogs. The study has shown that the dogs that received the Advaxis immunotherapy are living significantly longer than the dogs whose owners elected not to participate in